[go: up one dir, main page]

WO2003057233A1 - Composition destinee a la prevention ou au traitement de la mammite des bovins laitiers - Google Patents

Composition destinee a la prevention ou au traitement de la mammite des bovins laitiers Download PDF

Info

Publication number
WO2003057233A1
WO2003057233A1 PCT/KR2003/000031 KR0300031W WO03057233A1 WO 2003057233 A1 WO2003057233 A1 WO 2003057233A1 KR 0300031 W KR0300031 W KR 0300031W WO 03057233 A1 WO03057233 A1 WO 03057233A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
gum
chitosan
chitooligosaccharide
bromelain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2003/000031
Other languages
English (en)
Inventor
Jeong-Chan Ra
Kyung-Sun Kang
Yong-Ho Park
Hae-Jung Han
Jong-Eun Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RNL Life Science Ltd
Original Assignee
RNL Life Science Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RNL Life Science Ltd filed Critical RNL Life Science Ltd
Priority to AU2003202153A priority Critical patent/AU2003202153A1/en
Publication of WO2003057233A1 publication Critical patent/WO2003057233A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to a composition for preventing or treating mastitis of dairy cattle.
  • Mastitis is one of the most serious diseases that afflict dairy cows and caused by various pathogenic microorganisms e.g., Straphylococcus aureus, Streptococcus agalactiae, Streptococcus dysgalactiae, and Streptococcus uberis.
  • Infected cows suffer from inflamed mammary gland and produce less milk, and, further, the milk produced is of poor quality, containing an increased number of somatic cells such as neutrophils.
  • the number of somatic cells in milk can be used as a measure of the health condition of dairy cattle and the quality of milk.
  • the object of the present invention to provide a composition effectively preventing or treating mastitis, thereby decreasing the number of somatic cells in raw milk.
  • the present invention provides a composition for decreasing somatic cells in raw milk and effectively preventing or treating mastitis, comprising 0.1 to 20 wt % of chitosan-chitooligosaccharide and 0.1 to 10 wt% of bromelain as active ingredients.
  • the inventive composition may further comprise 0.01 to 10 wt% of licorice, 0.5 to 30 wt% of Zn or a salt thereof and/or 10 to 60 wt% of a fermented culture.
  • Chitosan-chitooligosaccharide employed in the present invention is as a form of chitosan which shows a broad antibiotic effect capable of lowering the number of somatic cells.
  • the ratio of chitosan to chitooligosaccharide is preferably 1: 0.5 to 1: 0.75.
  • chitooligosaccharide is prepared by enzymatically disintegrating chitin or chitosan into acetylglucosamine or glucosamine unit having a molecular weight of less than 3,000 dalton and is water-soluble.
  • the chitosan employed in the present invention promotes the differentiation of immunocytes, and especially increases the number of polymorphonuclear leukocyte (PMN), macrophage (M) and natural killer cell (NK) to enhance the antibiotic effects of PMN plus M and NK plus M as well as the inhibitory effect against other etiological factors.
  • PMN polymorphonuclear leukocyte
  • M macrophage
  • NK natural killer cell
  • composition of the present invention comprises bromelain which is a protease having anti-inflammatory activity.
  • Bromelain employed in the present invention is optionally coated with enteric coating agents soluble only in the intestine. Bromelain is absorbed through the intestine, but it is unstable in the highly acidic environment of the stomach of a ruminant animal such as dairy cattle. Accordingly, the coated bromelain is designed to be stable in such gastric acid environment and enhance the absorption in the intestine.
  • Bromelain employed in the present invention may be coated first with a 1 st aqueous coating agent at a low temperature, and then with a 2 nd coating agent, for an increased stability in the stomach and a controlled release in the intestine.
  • the 1 st aqueous coating agent may be sodium alginate, alginic acid, polymethylmetacrylate, e.g., Eudragait (L30D, LS30D) and Kollicoat MP (BASF), wheat protein, soybean protein, methylcellulose (MC), hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC), e.g., pharma coat and aqua coat, gums such as Guar gum, Locust bean gum, Xanthan gum, Gellan gum and Arabia gum or a mixture thereof.
  • the aqueous coating agents are water-soluble or water-dispersible and can be easily employed by using water as a solvent, avoiding the use of toxic organic solvents.
  • sodium alginate is preferred.
  • the 2 nd coating agent may be an enteric coating agent; a swell coating agent such as carbopol; and Arabia gum; or other release-control coating agents, and it is preferably a corn extract protein or an artificially processed material thereof, e.g., Zein-DP and prolamin; sodium alginate; alginic acid; polymethylmetacrylate, e.g., Eudragait (L30D, LS30D) and Kollicoat MP (BASF); shellac; hydroxypropylmethylcellulosephtalate (HPMCP); hydroxypropylmethylcellulose (HPMC); hydroxypropylmethyl- celluloseacetatesuccinate (HPMCAS); carboxymethylcellulose (CMC); hydroxypropylcellulose (HPC); celluloseacetatephtalate (CAP); ethyl
  • composition of the present invention may further comprise 0.01 to 10 wt% of licorice, which functions to mitigate inflammation.
  • composition of the present invention may still further comprise 0.5 to 30 wt% of Zn or a salt thereof.
  • the zinc or its salt is in the form of a chelate with methionine, acetate or protenate for improving the absorption rate thereof.
  • a Zn compound such as zinc oxide and zinc sulfate and an organozinc such as zinc methionine, zinc acetate and zinc protenate are preferred.
  • composition of the present invention may further comprise 10 to 60 wt% of a fermented culture, which is a dried culture medium containing microorganisms in a viable form.
  • a fermented culture which is a dried culture medium containing microorganisms in a viable form.
  • the microorganisms employed in the present invention may be Aspergillus oryzae, Aspergillus niger, Aspergillus terreus, Saccharomyces cerevisiae or Bacillus subtilis, and, Aspergillus oryzae which is known to enhance milk production, is preferred.
  • composition of the present invention may comprise formulating additives such as a solution adjuvant, a moisturizing agent, a diluent and the like, if necessary.
  • the solution adjuvant may be at least one selected from polyethyleneglycols, glycerin fatty acids, sorbitan fatty acid esters, propyleneglycol, glycerin, triethylcitrate, triacetin, cetyl alcohol or stearyl alcohol, and used in the amount of 0.5 to 50 wt% based on the weight of the total coated granules.
  • the moisturizing agent may be sorbitol, mannitol, xylitol or inositol, and the diluent may be corn starch, wheat shorts, dextrose, defatted rice bran or soybean meal.
  • composition of the present invention may be prepared by a process comprising the following steps of:
  • step (3) adding optional ingredients with the mixture obtained in step (2);
  • step 4) adding a carrier to the mixture obtained in step (3); and 5) pelletizing the mixture obtained in step (4).
  • bromelain may be coated in a flowing layer assembly apparatus.
  • a preferable embodiment of the present invention employs an aqueous solution of sodium alginate as the 1 st coating agent and a coating mixture of Zein-DP and ethanol as the 2 nd coating agent.
  • step (2) 0.1 to 10 wt% of the coated bromelain is mixed with 0.1 to
  • step (3) 0.5 to 30 wt% of zinc or a salt thereof, 0.01 to 10 wt% of licorice and/or 10 to 60 wt% of fermented culture are added to the mixture obtained in step (2) using a mixer at room temperature.
  • a carrier is mixed with the mixture obtained in step (3) using a ribbon mixer.
  • the carrier may be alfalfa, corn starch, gluten, wheat four or molasses.
  • step (5) the mixture obtained in step (4) is pelletized, preferably at a temperature of about 121 °C .
  • composition of the present invention may be administered to dairy cows by way of admixing with feedstuff, or formulated by mixing with pharmaceutically acceptable carriers or additives for oral administration or injection.
  • the formulation for oral administration may be in various forms e.g., powder, granule, tablet, capsule, solution such as drench, emulsion, and suspension.
  • the inventive composition for injection may comprise distilled water, ethyloleinate, ethanol, propyleneglycol or glycerine as a pharmaceutically acceptable carrier; ascorbic acid, sodium bisulfite, sodium pyrosulfite or tocopherol as an antioxidant; and phenylmercury nitrate, thimerosal, benzalkonium chloride, phenol, cresol, paraoxy methylbenzoate or benzyl alcohol as a preservative.
  • composition may further comprise conventional vitamins, saccharides such as glucose and lactose, starch, wheat shorts, vermiculite or various feed powders and liquid enzymes for animals in an acceptable amount.
  • saccharides such as glucose and lactose, starch, wheat shorts, vermiculite or various feed powders and liquid enzymes for animals in an acceptable amount.
  • the daily dosage of the active ingredient of chitosan-chitooligosaccharide ranges from 20 to 4,000 mg/animal in case of feedstuff additive pellet, and 1,000 to 2,000 g/ton of feedstuff in case of the powder or the granule.
  • the amount of the active ingredient actually administered should be determined in light of various relevant factors including the condition of the dairy cows to be treated, and, therefore, the dosage suggested above should not be construed to limit the scope of the invention in any way.
  • the composition of the present invention can be used for effective prevention or treatment of mastitis, leading to a marked decrease in the number of somatic cells in raw milk, as well as an increased milk productivity.
  • Example 1 The effect of chitosan-chitooligosaccharide on the death of causative pathogens of mastitis
  • MIC minimum inhibitory concentrations
  • TSB medium tryptic soy broth; bacto tryptone 17 g, bacto soytone 3 g, bacto dextrose 2.5 g, sodium chloride 5 g and dipotassium phosphate
  • TSB medium tryptic soy broth; bacto tryptone 17 g, bacto soytone 3 g, bacto dextrose 2.5 g, sodium chloride 5 g and dipotassium phosphate
  • Example 2 The controlling effect of the combined use of chitosan- chitooligosaccharide and bromelain on the causative pathogens of mastitis
  • Example 1 In order to check the controlling effect of the combination of chitosan- chitooligosaccharide and bromelain on the causative pathogens of mastitis, the MIC of the combination was measured by the procedure of Example 1. 1 mg/1 of 1000 CDU/mg bromelain (B) (Pineapple meal, Hong Mao Biochemical Co., Ltd., Taiwan) was combined with 0.1, 0.5, 1, 3, 5, 6, 7, 8, 9, 10, or 15 mg/1 of chitosan-chitooligosaccharide (C).
  • CDTJ Chip Digestion Unit
  • the amount of bromelain required for isolating 1 ⁇ g of tyrosine from casein at 37°C for 1 minute represents the enzymatic activity of bromelain
  • 1000 CDU means that 1 mg of bromelain isolates 1 mg of tyrosine.
  • Table 2 shows that the MIC of the chitosan-chitooligosaccharide and bromelain (C+B) combination is 8 to 9 mg/1 for each species of bacteria, which is lower than the MIC of chitosan-chitooligosaccharide alone.
  • Example 3 The effect of chitosan-chitooligosaccharide on the number of somatic cells in raw milk
  • Table 3 demonstrates that the number of somatic cells in the raw milk taken from the experimental groups is markedly lower than that of the control group. Specifically, 5, 7.5 and 10 mg groups showed 53.1%, 65.7% and 64.6% decrease in the number of somatic cells as compared to the control group, respectively. Accordingly, an optimal concentration of chitosan- chitooligosaccharide for lowering the number of somatic cells in raw milk was determined to be 7.5 mg/day.
  • Example 4 The effect of licorice in lowering the number of somatic cells
  • the experimental groups show lower somatic cell number than the control group.
  • Example 5 The effect of zinc in lowering the number of somatic cells
  • the experimental groups show lower somatic cell numbers than the control group.
  • the 100 and 200 mg groups show somatic cell numbers which were 51.1% and 50.8%> lower than that of the control group, respectively. Accordingly, an optimal concentration of zinc for lowering the number of somatic cells in raw milk was determined to be 100 mg/day.
  • Example 6 The stability of the coated bromelain in gastric acid
  • the pH in stomach of dairy cattle is 1 to 2, and digestion takes about 6 hours.
  • As the optimal pH for bromelain activity is 4.5 to 5.0, bromelain of the present invention was double-coated for the protection thereof in such a gastric environment as follows.
  • Uncoated and coated bromelains showed 300 and 900 CDU, respectively.
  • the double-coated bromelain according to the present invention was thus confirmed to be stable and maintain its enzymatic activity in the gastric acid.
  • Example 7 The effect of the coated bromelain in lowering the number of somatic cells
  • the experimental groups showed markedly lower somatic cell numbers in raw milk than the control group.
  • the 3, 6,. and 9 mg groups showed somatic cell numbers which are 51.2%, 62.35% and 63.07%o lower than that of the control group, respectively.
  • an optimal concentration of coated bromelain for lowering the number of somatic cells in raw milk was determined to be 9 mg/day.
  • Example 8 The effect of the combination of chitosan-chitooligosaccharide, zinc methionine and coated bromelain in lowering the number of somatic cells
  • the formulations were orally administered to respective experimental groups, while only water was fed to a control group. Each group consisted of 30 dairy cows, and milking was carried out for 8 weeks. The change in the number of somatic cells in raw milk was measured by the method of Example 3 and the results are shown in Table 7.
  • the number of somatic cells for the control group was fluctuated a little depending on the environmental change.
  • the experimental groups administered with the composition of the present invention showed a marked decrease in the number of somatic cells in raw milk as compared with the control group.
  • formulation A group shows a 62.4%) decrease in the number of somatic cell as compared to the control group
  • formulation B group a 69.6%> decrease, while the grade of the raw milk was improved from the 2nd or 3rd to 1st.
  • formulation B was found to be superior to formulation A.
  • Example 9 The effect of fermented culture on increasing milk production
  • Aspergillus oryzae (Genebiotech, Inc.) in lowering the number of somatic cells and increasing milk production was tested.
  • Aspergillus oryzae was cultured by a solid fermentation method (Raper, K.B. et al, The genus Aspergillus, R.E. Krieger Publishing company, Huntington, NY, USA, 1965). 200 g of the dried culture was added to formulation B of Example 7 to obtain formulation C.
  • Formulation B and formulation C were orally administered to respective experimental groups. Each group consisted of 40 dairy cows, and milking was carried out for 5 weeks. The change in the number of somatic cells in raw milk is shown in Table 8.
  • the experimental groups shows about 68% lower number of somatic cells than the control group, while the formulation B and C groups give 7.1 %> and 11.1% increases in milk production, respectively, as compared to the control group.
  • Example 10 The effect of the combination of chitosan-chitooligosaccharide, zinc methionine. coated bromelain, licorice and fermented culture in lowering the number of somatic cells
  • Formulation D containing 11.4 wt%> of chitosan-chitooligosaccharide, 1 wt% of coated bromelain, 10 wt% of zinc methionine, 10 wt% of licorice and 20 wt% of fermented culture was prepared.
  • the formulation was orally administered to experimental groups, while only water was fed to control groups.
  • Experimental groups and control groups were respectively consisted of 74 and 27 dairy cows collected from 5 farms as shown in Table 9 and milking was carried out every 2 weeks for 10 weeks. The change in the number of somatic cells in raw milk was measured by the method of Example 3 and the results are shown in Table 9.
  • the experimental groups administered with the composition of the present invention showed a marked decrease in the number of somatic cells in raw milk as compared with the control groups. Specifically, the experimental groups shows a 14.0%, 28.2%, 36%, 38.5% and 34.8% decrease in the number of somatic cells 2, 4, 6, 8 and 10 weeks after the administration of formulation D, respectively. The number of somatic cells started to decrease 2 weeks after the administration and lowest 6 to 8 weeks after the administration.
  • Example 11 The effect of the combination of chitosan-chitooligosaccharide, zinc methionine. coated bromelain, licorice and fermented culture in lowering the number of somatic cells and milk productibility Formulation D of Example 10 was orally administered to 623 dairy cows for 42 days in Corona, California, U.S.A. The daily dosage of administration was 20g/cow. Milking was carried out for 6 weeks and the change in the number of somatic cells in raw milk and the amount of produced milk are shown in Table 10.
  • the composition of the present invention induced a marked decrease in the number of somatic cells in raw milk and an increase in the amount of milk production.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une composition comprenant comme ingrédients actifs 0,1 à 20 % en poids de chitosane-chitooligosaccharide et 0,1 à 10 % en poids de broméline. Cette composition est utile pour réduire le nombre de cellules somatiques dans le lait cru et prévenir ou traiter la mammite.
PCT/KR2003/000031 2002-01-10 2003-01-09 Composition destinee a la prevention ou au traitement de la mammite des bovins laitiers Ceased WO2003057233A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003202153A AU2003202153A1 (en) 2002-01-10 2003-01-09 Composition for preventing or treating mastitis of dairy cattle

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2002-0001474 2002-01-10
KR10-2002-0001474A KR100474945B1 (ko) 2002-01-10 2002-01-10 젖소의 원유 중 체세포 감소용 및 유방염의 예방 또는치료용 조성물

Publications (1)

Publication Number Publication Date
WO2003057233A1 true WO2003057233A1 (fr) 2003-07-17

Family

ID=19718363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2003/000031 Ceased WO2003057233A1 (fr) 2002-01-10 2003-01-09 Composition destinee a la prevention ou au traitement de la mammite des bovins laitiers

Country Status (3)

Country Link
KR (1) KR100474945B1 (fr)
AU (1) AU2003202153A1 (fr)
WO (1) WO2003057233A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020708A1 (fr) * 2003-08-27 2005-03-10 Mw Encap Limited Formulation amelioree pour l'elaboration d'un revetement gastro-resistant
WO2005023240A3 (fr) * 2003-09-04 2005-10-06 Dana Flavin-Koenig Preparation pharmaceutique combinee contenant de l'acide glycyrrhizique, du zinc et un compose renfermant un groupe thiol ou un groupe pouvant etre metabolise en groupe thiol
FR2900054A1 (fr) * 2006-04-21 2007-10-26 Kitozyme Sa Utilisation de polysaccharides d'origine fongique comme composition pharmaceutique ou complements alimentaires pour la sante humaine et animale
WO2008045920A2 (fr) 2006-10-10 2008-04-17 Wisconsin Alumni Research Foundation Préparation d'obturation intra-mammaire de trayon et procédé d'utilisation de celle-ci pour réduire ou éliminer les défauts visuels dans des fromages vieillis
CN102885044A (zh) * 2011-10-28 2013-01-23 海南正业中农高科股份有限公司 一种用于防治稻飞虱的壳寡糖组合物及其用途和方法
CN103285131A (zh) * 2013-07-02 2013-09-11 赵长杰 一种治疗乳腺炎的中药洗液
WO2014091138A1 (fr) * 2012-12-14 2014-06-19 Lesaffre Et Compagnie Chitine ou ses derives pour la prevention et/ou le traitement de parasitoses
CN104313004A (zh) * 2014-10-20 2015-01-28 内蒙古阜丰生物科技有限公司 一种处理黄原胶生产污水的制剂
US9956167B2 (en) 2009-04-08 2018-05-01 Wisconsin Alumni Research Foundation Intra-mammary teat sealant formulation and method of using same to reduce or eliminate visual defects in aged cheeses
US10064870B2 (en) 2015-11-03 2018-09-04 Zoetis Services Llc Sol-gel polymer composites and uses thereof
US10500168B2 (en) * 2003-11-10 2019-12-10 Beiersdorf Ag Use of licochalcone a for treatment of rosacea
US11497942B2 (en) 2003-12-04 2022-11-15 Beiersdorf Ag Cosmetic or dermatological preparation comprising a combination of a dye and an anti-inflammatory active ingredient
WO2023148204A1 (fr) * 2022-02-03 2023-08-10 Société des Produits Nestlé S.A. Forme posologique orale avec enveloppe de capsule gastro-résistante

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100573396B1 (ko) * 2002-11-04 2006-04-25 (주)국송 가축의 체세포를 감소시킬 수 있으며 애견의 장염성설사를 예방-치료할 수 있는 약제 및 이의 제조방법
KR100576074B1 (ko) * 2004-02-27 2006-05-10 대한민국 생리활성을 촉진하여 젖소에서 착유한 우유 내의 체세포수를 저감하는 젖소용 사료첨가제
KR101979358B1 (ko) * 2017-01-03 2019-05-15 서울대학교산학협력단 소 유방염 치료제 조성물
CN112514916A (zh) * 2020-11-30 2021-03-19 云南省微生物发酵工程研究中心有限公司 一种防治东亚飞蝗的悬浮剂

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57180602A (en) * 1981-04-30 1982-11-06 Nippon Soda Co Ltd Production of water-soluble chitosan derivative and film-forming agent comprising same
JPH04169529A (ja) * 1990-10-30 1992-06-17 Nippon Soda Co Ltd 家蓄の乳房炎を予防する方法
EP0692253A1 (fr) * 1992-08-07 1996-01-17 Nippon Soda Co., Ltd. Agent prophylactique pour la mastite des animaux domestiques
KR980008232A (ko) * 1996-07-01 1998-04-30 김찬 키토산 또는 키틴 유도체를 이용한 젖소의 유방질환 치료제와 사용법
KR20010058414A (ko) * 1999-12-09 2001-07-06 이동규 동물용 복합항균제 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57180602A (en) * 1981-04-30 1982-11-06 Nippon Soda Co Ltd Production of water-soluble chitosan derivative and film-forming agent comprising same
JPH04169529A (ja) * 1990-10-30 1992-06-17 Nippon Soda Co Ltd 家蓄の乳房炎を予防する方法
EP0692253A1 (fr) * 1992-08-07 1996-01-17 Nippon Soda Co., Ltd. Agent prophylactique pour la mastite des animaux domestiques
KR980008232A (ko) * 1996-07-01 1998-04-30 김찬 키토산 또는 키틴 유도체를 이용한 젖소의 유방질환 치료제와 사용법
KR20010058414A (ko) * 1999-12-09 2001-07-06 이동규 동물용 복합항균제 조성물

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9629802B2 (en) 2003-08-27 2017-04-25 Sensient Colors Llc Formulation for providing an enteric coating material
US8846087B2 (en) 2003-08-27 2014-09-30 Sensient Colors Llc Formulation for providing an enteric coating material
WO2005020708A1 (fr) * 2003-08-27 2005-03-10 Mw Encap Limited Formulation amelioree pour l'elaboration d'un revetement gastro-resistant
US8268363B2 (en) 2003-09-04 2012-09-18 Dana Flavin-Koenig Pharmaceutical combination preparation containing glycyrrhizine, zinc, and a compound comprising a thiol group or a group that is metabolized thereto
WO2005023240A3 (fr) * 2003-09-04 2005-10-06 Dana Flavin-Koenig Preparation pharmaceutique combinee contenant de l'acide glycyrrhizique, du zinc et un compose renfermant un groupe thiol ou un groupe pouvant etre metabolise en groupe thiol
US10500168B2 (en) * 2003-11-10 2019-12-10 Beiersdorf Ag Use of licochalcone a for treatment of rosacea
US11497942B2 (en) 2003-12-04 2022-11-15 Beiersdorf Ag Cosmetic or dermatological preparation comprising a combination of a dye and an anti-inflammatory active ingredient
FR2900054A1 (fr) * 2006-04-21 2007-10-26 Kitozyme Sa Utilisation de polysaccharides d'origine fongique comme composition pharmaceutique ou complements alimentaires pour la sante humaine et animale
WO2007122187A3 (fr) * 2006-04-21 2007-12-21 Kitozyme Sa Utilisation de polysaccharides d'origine fongique comme composition pharmaceutique ou complements alimentaires
US11491185B2 (en) 2006-10-10 2022-11-08 Wisconsin Alumni Research Foundation Intra-mammary teat sealant formulation and method of using same to reduce or eliminate visual defects in aged cheeses
AU2007307778B2 (en) * 2006-10-10 2013-04-18 Wisconsin Alumni Research Foundation Intra-mammary teat sealant formulation and method of using same to reduce or eliminate visual defects in aged cheeses
EP2450045A1 (fr) * 2006-10-10 2012-05-09 Wisconsin Alumni Research Foundation Formule d'étanchéité de tétine intra-mammaire et son procédé d'utilisation pour réduire ou supprimer les défauts visuels chez les fromages vieillis
KR101409636B1 (ko) 2006-10-10 2014-06-18 위스콘신 얼럼나이 리서어치 화운데이션 유방내 유두 봉합제 및 숙성된 치즈에서 시각적 결함을 감소 또는 저하시키기 위해 이를 사용하는 방법
US7906138B2 (en) 2006-10-10 2011-03-15 Wisconsin Alumni Research Foundation Intra-mammary teat sealant formulation and method of using same to reduce or eliminate visual defects in aged cheeses
US8795714B2 (en) 2006-10-10 2014-08-05 Wisconsin Alumni Research Foundation Intra-mammary teat sealant formulation and method of using same to reduce or eliminate visual defects in aged cheeses
JP2010505595A (ja) * 2006-10-10 2010-02-25 ウイスコンシン アルムニ リサーチ ファウンデイション 乳房内乳首シーラント製剤、およびこれを用いて、熟成チーズの視覚的欠陥を抑制または除去する方法
WO2008045920A3 (fr) * 2006-10-10 2008-09-18 Wisconsin Alumni Res Found Préparation d'obturation intra-mammaire de trayon et procédé d'utilisation de celle-ci pour réduire ou éliminer les défauts visuels dans des fromages vieillis
WO2008045920A2 (fr) 2006-10-10 2008-04-17 Wisconsin Alumni Research Foundation Préparation d'obturation intra-mammaire de trayon et procédé d'utilisation de celle-ci pour réduire ou éliminer les défauts visuels dans des fromages vieillis
US9956167B2 (en) 2009-04-08 2018-05-01 Wisconsin Alumni Research Foundation Intra-mammary teat sealant formulation and method of using same to reduce or eliminate visual defects in aged cheeses
US10744085B2 (en) 2009-04-08 2020-08-18 Wisconsin Alumni Research Foundation Intra-mammary teat sealant formulation and method of using same to reduce or eliminate visual defects in aged cheeses
CN102885044A (zh) * 2011-10-28 2013-01-23 海南正业中农高科股份有限公司 一种用于防治稻飞虱的壳寡糖组合物及其用途和方法
CN102885044B (zh) * 2011-10-28 2014-03-19 海南正业中农高科股份有限公司 一种用于防治稻飞虱的壳寡糖组合物及其用途和方法
FR2999428A1 (fr) * 2012-12-14 2014-06-20 Lesaffre & Cie Chitine ou derives de chitine pour utilisation dans la prevention et/ou le traitement de parasitoses
US9717751B2 (en) 2012-12-14 2017-08-01 Lesaffre Et Compagnie Chitin or derivatives thereof for the prevention and/or treatment of parasitoses
CN104870002B (zh) * 2012-12-14 2019-07-23 乐斯福公司 用于预防和/或治疗寄生虫病的甲壳素或其衍生物
CN104870002A (zh) * 2012-12-14 2015-08-26 乐斯福公司 用于预防和/或治疗寄生虫病的甲壳素或其衍生物
WO2014091138A1 (fr) * 2012-12-14 2014-06-19 Lesaffre Et Compagnie Chitine ou ses derives pour la prevention et/ou le traitement de parasitoses
CN103285131A (zh) * 2013-07-02 2013-09-11 赵长杰 一种治疗乳腺炎的中药洗液
CN104313004A (zh) * 2014-10-20 2015-01-28 内蒙古阜丰生物科技有限公司 一种处理黄原胶生产污水的制剂
US10064870B2 (en) 2015-11-03 2018-09-04 Zoetis Services Llc Sol-gel polymer composites and uses thereof
US10729698B2 (en) 2015-11-03 2020-08-04 Zoetis Services Llc Sol-gel polymer composites and uses thereof
WO2023148204A1 (fr) * 2022-02-03 2023-08-10 Société des Produits Nestlé S.A. Forme posologique orale avec enveloppe de capsule gastro-résistante

Also Published As

Publication number Publication date
KR20030061102A (ko) 2003-07-18
KR100474945B1 (ko) 2005-03-10
AU2003202153A1 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
WO2003057233A1 (fr) Composition destinee a la prevention ou au traitement de la mammite des bovins laitiers
US20250186522A1 (en) Compositions and methods for promoting a healthy microbial flora in a mammal
CN105358166B (zh) 用于反刍动物的乳腺炎的预防剂或治疗剂
EP2397147B1 (fr) Alimentation animale prophylactique et/ou thérapeutique des maladies causes par la bactéria clostridium de l'animal domestique ainsi qu'agent anti-clostridium
US20210030818A1 (en) Compositions for use in balancing microbiome
US20090053317A1 (en) Microparticulate systems for the oral administration of biologically active substances
CN106822033A (zh) 以玉米芯粉为囊心材料制备含药物的囊心物及其微囊
CN107484878A (zh) 一种微生物微胶囊的制备方法及其在饲料中的应用
JP2003516133A (ja) 動物飼料用添加剤
CN108669298A (zh) 一种饲用益生菌微胶囊及其制备方法和应用
CN111494601A (zh) 一种过瘤胃的肠溶性抗菌肽颗粒及制备方法
CN115487164B (zh) 一种可用于无人机投放的吡喹酮丸剂
JP2002507123A (ja) プロバイオティックの有効性を改良する方法、栄養添加物の調製、およびそれを含む動物飼料
CN120590479A (zh) 抗菌肽及其应用
CN108125979A (zh) 一种具有杀菌保护功能的组合物及其应用
CN111821322A (zh) 一种可替代抗生素的禽用微生态口服制剂及其应用
CN112843011B (zh) 一种替米考星预混剂及其制备方法
CN112515050B (zh) 一种含重组人溶菌酶的抑菌型动物生长促进剂及其应用
US11337441B2 (en) Probiotic composition for use in a feed additive
CN106666151A (zh) 防控仔猪腹泻的无抗添加剂及其制备方法
KR20030021298A (ko) 동물용 면역증진 및 정장용 조성물
JPS60199397A (ja) グリコペプチド系抗生物質およびその製造方法
CN108553635B (zh) 一种猪源抗菌肽pmap-36缓释胶囊
CN118976004A (zh) 一种纳米材料包覆抗菌肽的制备方法
US20210235722A1 (en) Gut bacterium-based treatment to increase poultry gut health and food safety

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP